Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 67.32 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: purified talc; hypromellose phthalate; triethyl citrate; titanium dioxide; hyprolose; hypromellose; crospovidone; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; iron oxide yellow; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: hyprolose; purified talc; triethyl citrate; crospovidone; titanium dioxide; hypromellose phthalate; hypromellose; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: purified talc; crospovidone; titanium dioxide; hypromellose; triethyl citrate; hyprolose; hypromellose phthalate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - duloxetine hydrochloride, quantity: 67.32 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: crospovidone; titanium dioxide; hyprolose; hypromellose phthalate; triethyl citrate; hypromellose; purified talc; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; iron oxide yellow; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: titanium dioxide; purified talc; hyprolose; hypromellose; hypromellose phthalate; crospovidone; triethyl citrate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - aprepitant - capsules - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; titanium dioxide; gelatin; purified talc - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin trihydrate, quantity: 287 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; titanium dioxide; purified talc - indications as at 6 november 2003: cilamox is indicated for the treatment of infections due to susceptible strains of the sensitive organisms. gram-negative: h. influenzae, e coli, pr. mirabilis, and n. gonorrhoeae. gram-positive: streptococcus species, s. pneumoniae, non-penicllinase producing staphlococci and bacillus anthracis. note 1: cilamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to cilamox should be performed. note 2: penicillins are now generally regarded only as adjunctive to some other established first-line antibiotic therapy in the treatment and post-exposure prophylaxis of anthrax, because of concerns of constitutive and inducible beta-lactamase in bacillus anthracis. if use of amoxycillin is contemplated, appropriate bacteriological studies must be performed by a reliable and established test method. amoxycillin may then be suitable if the specific b. anthracis strain has been shown definitively to be sensitive to penicillin/amaxycillin.